​

Maravai LifeSciences (MRVI) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Maravai LifeSciences Revenue Highlights

Latest Revenue (Y)

$259.19M

Latest Revenue (Q)

$41.63M

Main Segment (Y)

Nucleic Acid Production Segment

Main Geography (Y)

North America

Maravai LifeSciences Revenue by Period

Maravai LifeSciences Revenue by Year

DateRevenueChange
2024-12-31$259.19M-10.30%
2023-12-31$288.94M-67.28%
2022-12-31$883.00M10.48%
2021-12-31$799.24M181.33%
2020-12-31$284.10M98.48%
2019-12-31$143.14M15.59%
2018-12-31$123.83M-

Maravai LifeSciences generated $259.19M in revenue during NA 2024, up -10.30% compared to the previous quarter, and up 181.07% compared to the same period a year ago.

Maravai LifeSciences Revenue by Quarter

DateRevenueChange
2025-09-30$41.63M-12.17%
2025-06-30$47.40M1.17%
2025-03-31$46.85M-16.94%
2024-12-31$56.41M-13.49%
2024-09-30$65.20M-11.17%
2024-06-30$73.40M14.37%
2024-03-31$64.18M-13.44%
2023-12-31$74.14M10.88%
2023-09-30$66.86M-2.97%
2023-06-30$68.91M-12.79%
2023-03-31$79.03M-61.40%
2022-12-31$204.71M7.03%
2022-09-30$191.26M-21.20%
2022-06-30$242.73M-0.64%
2022-03-31$244.29M6.94%
2021-12-31$228.44M11.54%
2021-09-30$204.81M-5.95%
2021-06-30$217.78M46.94%
2021-03-31$148.21M50.69%
2020-12-31$98.35M11.94%
2020-09-30$87.86M87.31%
2020-06-30$46.91M-8.00%
2020-03-31$50.98M41.77%
2019-12-31$35.96M-

Maravai LifeSciences generated $41.63M in revenue during Q3 2025, up -12.17% compared to the previous quarter, and up 56.72% compared to the same period a year ago.

Maravai LifeSciences Revenue Breakdown

Maravai LifeSciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21
Nucleic Acid Production Segment$196.34M$224.77M--
Biologics Safety Testing Segment$62.84M$64.18M--
Protein Detection Segment----
Shipping and Handling--$3.20M$3.60M

Maravai LifeSciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Nucleic Acid Production Segment (75.75%), and Biologics Safety Testing Segment (24.25%).

Quarterly Revenue by Product

Product/ServiceSep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Biologics Safety Testing Segment$16.28M$16.31M$18.10M$29.42M$15.25M$18.16M$15.32M$15.64M$15.65M$17.57M$15.42M$16.38M$17.48M$20.64M$15.93M$16.63M$18.21M$17.65M
Nucleic Acid Production Segment$25.35M$31.09M$28.75M$100.38M$49.95M$46.02M$58.83M$51.23M$53.27M$61.45M$189.29M$174.88M$225.25M$223.65M$212.51M$182.90M$192.52M$123.93M
Protein Detection Segment--------------$5.28M$7.05M$6.63M-

Maravai LifeSciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Nucleic Acid Production Segment (60.90%), and Biologics Safety Testing Segment (39.10%).

Maravai LifeSciences Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23
Asia Pacific$89.38M$97.44M
EMEA$42.05M$49.92M
Latin And Central America$662.00K$527.00K
North America$127.09M$141.06M

Maravai LifeSciences's latest annual revenue breakdown by geography, as of Dec 24: North America (49.03%), Asia Pacific (34.48%), EMEA (16.23%), and Latin And Central America (0.26%).

Quarterly Revenue by Country

CountrySep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Mar 21
Asia Pacific$8.34M$8.16M$10.56M$45.32M$22.92M$21.14M$72.82M$24.62M$15.98M
North America$25.03M$30.64M$29.27M$59.03M$34.69M$33.37M$106.54M$34.52M$78.30M
Latin And Central America$296.00K$205.00K$146.00K$230.00K$125.00K$307.00K$422.00K$105.00K$220.00K
EMEA$7.97M$8.39M$6.88M$25.23M$7.46M$9.37M$42.30M$7.62M$53.72M

Maravai LifeSciences's latest quarterly revenue breakdown by geography, as of Sep 25: North America (60.12%), Asia Pacific (20.03%), EMEA (19.14%), and Latin And Central America (0.71%).

Maravai LifeSciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRVIMaravai LifeSciences$259.19M$41.63M
DNAGinkgo Bioworks$227.04M$49.60M
IOVAIovance Biotherapeutics$164.07M$67.45M
VIRVir Bio$74.20M$240.00K
KURAKura Oncology$53.88M$20.75M
PRMEPrime Medicine$2.98M$1.23M
SEPNSepterna$1.07M$21.50M
LENZLENZ Therapeutics-$5.00M
REPLReplimune Group--
BCAXBicara Therapeutics--
TYRATyra Biosciences--

MRVI Revenue FAQ

What is Maravai LifeSciences’s yearly revenue?

Maravai LifeSciences's yearly revenue for 2024 was $259.18M, representing a decrease of -10.30% compared to 2023. The company's yearly revenue for 2023 was $288.94M, representing a decrease of -67.28% compared to 2022. MRVI's yearly revenue for 2022 was $883M, representing an increase of 10.48% compared to 2021.

What is Maravai LifeSciences’s quarterly revenue?

Maravai LifeSciences's quarterly revenue for Q3 2025 was $41.63M, a -12.17% decrease from the previous quarter (Q2 2025), and a -36.15% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $47.4M, a 1.17% increase from the previous quarter (Q1 2025), and a -35.43% decrease year-over-year (Q2 2024). MRVI's quarterly revenue for Q1 2025 was $46.85M, a -16.94% decrease from the previous quarter (Q4 2024), and a -27.00% decrease year-over-year (Q1 2024).

What is Maravai LifeSciences’s revenue growth rate?

Maravai LifeSciences's revenue growth rate for the last 3 years (2022-2024) was -70.65%, and for the last 5 years (2020-2024) was -8.77%.

What are Maravai LifeSciences’s revenue streams?

Maravai LifeSciences's revenue streams in c 24 are Nucleic Acid Production Segment, and Biologics Safety Testing Segment. Nucleic Acid Production Segment generated $196.34M in revenue, accounting 75.75% of the company's total revenue, down -12.65% year-over-year. Biologics Safety Testing Segment generated $62.84M in revenue, accounting 24.25% of the company's total revenue, down -2.09% year-over-year.

What is Maravai LifeSciences’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Maravai LifeSciences was Nucleic Acid Production Segment. This segment made a revenue of $196.34M, representing 75.75% of the company's total revenue.